A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

NCT04435600 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Risankizumab
DRUG: Ustekinumab

Sponsor

AbbVie